VB0.F Viva Biotech Holdings
- Market cap
- EUR 301M
- P/E
- 14.4x
- P/B
- 0.58x
- ROE
- 5.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is VB0.F undervalued?
Graham numberVB0.F trades 39.2% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Viva Biotech Holdings fundamental analysis
No fundamental analysis for Viva Biotech Holdings yet.
Viva Biotech Holdings stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Viva Biotech Holdings
Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacology and DMPK; chemistry services, such as medicinal and synthetic chemistry, purification preparation, and computer-aided drug design ser…
Full company profileViva Biotech Holdings financial statements
Viva Biotech Holdings annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 96.5M | 148M | 210M | 323M | 697M | 2.10B | 2.38B | 2.16B | 1.99B | 1.73B |
| Gross Profit | 54.1M | 86.2M | 105M | 156M | 305M | 651M | 816M | 738M | 687M | 656M |
| Operating Income | 29.1M | 57.4M | 30.2M | 44.0M | 125M | 272M | 312M | 256M | 270M | 212M |
| EBITDA | - | 93.2M | 116M | 317M | -224M | 531M | -89.0M | 332M | 563M | 567M |
| Net Income | 24.5M | 76.3M | 90.6M | 266M | -387M | 288M | -528M | -116M | 167M | 220M |
| EPS | - | 0.05 | 0.06 | 0.17 | -0.20 | 0.15 | -0.28 | -0.05 | 0.08 | 0.10 |
| Balance Sheet | ||||||||||
| Total Assets | 102M | 202M | 529M | 1.90B | 8.15B | 8.04B | 7.92B | 7.45B | 7.05B | 7.20B |
| Total Liabilities | 25.3M | 49.6M | 278M | 121M | 4.40B | 4.13B | 4.32B | 3.76B | 3.23B | 3.19B |
| Shareholders' Equity | 76.5M | 153M | 251M | 1.78B | 3.76B | 3.91B | 3.60B | 3.69B | 3.80B | 4.00B |
| Cash & Short-term Investments | 13.4M | 29.8M | 156M | 904M | 2.31B | 801M | 679M | 1.04B | 942M | 1.09B |
| Cash Flow | ||||||||||
| Operating Cash Flow | 21.1M | 27.9M | 12.1M | 46.0M | 43.2M | 77.8M | 386M | 383M | 374M | 232M |
| Capital Expenditure | 7.34M | 18.9M | 46.9M | 56.2M | 593M | 565M | 249M | 188M | 192M | 123M |
| Free Cash Flow | - | 8.97M | -34.8M | -15.8M | -586M | -488M | 137M | 196M | 182M | 110M |
| Ratios | ||||||||||
| ROE | 32.0% | 49.9% | 36.0% | 15.0% | -10.3% | 7.3% | -14.7% | -3.1% | 4.4% | 5.5% |
| ROA | 24.0% | 37.7% | 17.1% | 14.0% | -4.7% | 3.6% | -6.7% | -1.6% | 2.4% | 3.1% |
| Net Profit Margin | 25.4% | 51.4% | 43.1% | 82.3% | -55.5% | 13.7% | -22.2% | -5.4% | 8.4% | 12.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Viva Biotech Holdings dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 16, 2021
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | CNY 16.3M | 0.01 | 5.7% |
| 2020 | CNY 51.8M | 0.03 | - |
| 2019 | CNY 15.1M | 0.01 | 5.7% |
| 2018 | EUR 15.1M | 0.01 | 16.7% |
| 2017 | EUR 15.1M | 0.01 | 19.8% |
| 2016 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Viva Biotech Holdings
- Insiders 43.53%
- Institutions 8.59%
- Public & others 47.88%
- Shares outstanding 2.09B
- Free float 1,000M
Viva Biotech Holdings company profile
- Company name
- Viva Biotech Holdings
- Ticker
- VB0.F
- ISIN
- KYG9390W1015
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,213
- Fiscal year end
- December
- Address
- No.735, Ziping Road, Shanghai, China, 201318
- Phone
- 86 21 6089 3288
- Website
- vivabiotech.com.cn
About Viva Biotech Holdings
Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacology and DMPK; chemistry services, such as medicinal and synthetic chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody/biologics research and development services comprising recombinant protein expression platform, antibody discovery and affinity maturation, assay platform, antibody production and identification platform, and antigen-antibody structural resolution platform solutions. It also offers PROTAC/molecular glue services, including protein preparation and complex structure determination, ADME & PK/PD studies of PROTAC molecules, and XDC platforms, such as XDC conjugation and quality study, and XDC chemistry research and development. In addition, the company offers contract development and manufacturing services comprising integrated services for small molecule active pharmaceutical ingredients, formulation development and production services, and pharmaceutical analysis services, as well as CMC filing, global filing registration support, and other services. Further, it provides research services. The company was incorporated in 2008 and is headquartered in Shanghai, China.
Viva Biotech Holdings management
10- Dr. Chen Cheney Mao Ph.D.Chairman & CEO · born 1962
- Mr. Ying Wu M.B.A.Executive VP & Executive Director · born 1964
- Dr. Delin Ren Ph.D.Executive Director · born 1961
- Mr. Wei XiongChief Financial Officer · born 1984
- Dr. Susan Chen Ph.D.Chief Technology Officer
- Dr. Zhixiong Ye Ph.D.Chief Scientific Officer · born 1961
- Mr. Jianhua Cai Ph.D.Senior Vice President of Via Biotech Shanghai
- Jianguo Ma Ph.D.Senior VP & President of Shanghai Langhua Pharmaceutical
- Mr. Xianyong Bu Ph.D.CBO & EVP of Viva Biotech (Shanghai)
- Dr. Rongqiang Liu Ph.D.Senior Vice President of Via Biotech Shanghai · born 1966